GYRE
Gyre Therapeutics Inc.
6.80$
-4.0%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 3.7% | 4.6% | 3.6% | 3.1% | 3.8% | 4.2% | 4.1% | 3.9% | 5.3% | 4.7% | 5.4% | 7.6% | 5.7% | |
| 96.3% | 95.4% | 96.4% | 96.9% | 96.2% | 95.8% | 95.9% | 96.1% | 94.7% | 95.3% | 94.6% | 92.4% | 94.3% | |
| 9.4% | 16.8% | 8.0% | 13.3% | 10.9% | 13.3% | 14.0% | 28.1% | 7.7% | 12.9% | 29.9% | 65.7% | 27.7% | |
| 3.6% | 37.0% | 12.5% | 13.6% | 15.0% | 19.6% | 22.5% | 24.5% | 14.1% | 18.0% | 32.1% | 27.0% | 21.9% | |
| 56.5% | 432.9% | 66.7% | 84.0% | 79.6% | 93.6% | 85.6% | 103.7% | 72.0% | 95.0% | 136.1% | 141.8% | 108.3% | |
| 39.8% | -337.5% | 29.7% | 12.9% | 16.6% | 2.4% | 10.3% | -7.5% | 22.7% | 0.3% | -41.5% | -49.3% | -14.0% | |
| – | – | – | – | – | 1.3% | – | – | 3.5% | – | – | – | – | |
| 34.9% | -369.4% | 45.9% | 23.9% | 15.4% | 2.8% | 21.0% | -5.3% | 25.0% | -0.2% | -41.0% | -49.6% | -13.5% | |
| 11.5% | 2.6% | 9.4% | 5.9% | 4.2% | 0.7% | 4.1% | 2.2% | 5.5% | 3.5% | -2.8% | -0.6% | 1.8% | |
| 12.4% | -372.1% | 27.7% | 14.0% | 4.4% | -0.4% | 12.2% | 2.0% | 11.8% | -4.6% | -38.3% | -36.4% | -14.5% | |
| 35.5% | -18.0% | 47.5% | 24.9% | 17.3% | 4.1% | 23.4% | -4.1% | 27.1% | 1.7% | -38.0% | -49.4% | -11.7% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.